Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04774419 · ClinicalTrials.gov registry record · Phase 2

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

A Phase 2 study of Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
62
Enrollment target
7
Study locations

NCT04774419: Recruiting Phase 2 study of Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04774419 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 62 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04774419, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
62 participants
Enrollment target
7
Study locations

Study Summary

This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.

Primary Outcome

6-18 patients will be enrolled during a safety run-in period to assess toxicities. (NCI Common Terminology Criteria for Adverse Events version 5.0)

Conditions Studied

Interventions

  • DRUG Dostarlimab
  • RADIATION Intensity modulated radiation therapy (IMRT)
  • RADIATION Hypofractionated IMRT

Study Locations (7)

New York

  • Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activites) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2021-04-02
Est. Completion 2027-02
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT04774419 shows while recruiting

NCT04774419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dostarlimab is the first listed.

NCT04774419 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT04774419 about?

NCT04774419 is a clinical study titled "Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery". This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.

What is the current status of trial NCT04774419?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-04-02. Estimated completion is 2027-02.

What conditions does trial NCT04774419 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT04774419?

The interventions under investigation include: Dostarlimab (DRUG), Intensity modulated radiation therapy (IMRT) (RADIATION), Hypofractionated IMRT (RADIATION).

Who is sponsoring clinical trial NCT04774419?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04774419 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04774419's enrollment target sits among peer trials

62 114th of 181 higher than 67 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04774419, the US trial registry maintained by the National Library of Medicine. NCT04774419 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.